Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 7Leukemia 4Multiple Myeloma 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Biphenotypic, Acute 1Hematologic Diseases 1Hemangiosarcoma 1Castrate-resistant Metastatic Prostate Cancer 1Blast Crisis 1

Interventions

Gemcitabine 2Docetaxel 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2spartalizumab 1peginterferon alfa-2a 1balstilimab 1RNA, Messenger 1Paclitaxel 1Ipilimumab 1Granulocyte Colony-Stimulating Factor 1Glutamine 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Hemangiosarcoma × Granulocyte Colony-Stimulating Factor × Clear all
NCT05799612 2026-02-13

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡